LABORATORY CHARACTERISTICS OF A MULTISYSTEM INFLAMMATORY SYNDROME ASSOCIATED WITH SARS-COV-2 IN CHILDREN AND THEIR CORRECTION

Abstract

The acute course of COVID-19 with features of Kawasaki disease and toxic shock syndrome, hyperreactive inflammation leading to multiple organ failure and shock is referred to as multisystem inflammatory syndrome (MIS) in children associated with COVID-19. In the second or third week, a complex of severe symptoms develops. Medicines for the treatment of children are less than for adults due to age restrictions. Therefore, timely diagnosis of children with coronavirus infection and MIS associated with COVID-19 is a relevant and necessary component of timely and effective treatment. The study was performed in a clinical and diagnostic laboratory. The patients were divided into two groups: the first group – 7 children aged 2 to 11 years with a confirmed diagnosis of MIS associated with COVID-19 and who received ampicillin (200 mg/kg/day for 4 injections over 7 days) and the second group – 8 children aged 2 to 10 years with a confirmed diagnosis of MIS associated with COVID-19 and receiving ceftriaxone (100 mg/kg/day in 2 administrations for 7 days). The control group – 8 patients from the experimental groups before the start of antibiotic therapy. A decrease in the number of leukocytes was noted in the experimental groups, but the indicators reached normal values on the 7th day only in the second group, the same situation was with the number of neutrophils, which turned out to be statistically reliable. The inflammatory process tended to decline, as ESR, C-reactive protein, and procalcitonin levels decreased, but this was more pronounced in the second experimental group. According to our study, the use of ceftriaxone in children with MIS associated with the SARS-CoV-2 virus is more effective, because its use corrected laboratory parameters towards the norm.